Cutler Group LP Assembly Biosciences, Inc. Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 19, 2021	SELL	$3.8 - $4.56 $1,900 - $2,280	-500 Reduced 71.43%	200 $0
Q1 2021 Apr 26, 2021	BUY	$4.33 - $6.63 $433 - $663	100 Added 16.67%	700 $3,000
Q4 2020 Jan 21, 2021	BUY	$4.87 - $17.29 $306 - $1,089	63 Added 11.73%	600 $3,000
Q2 2020 Jul 22, 2020	SELL	$14.57 - $23.96 $57,740 - $94,953	-3,963 Reduced 88.07%	537 $12,000
Q1 2020 May 07, 2020	BUY	$10.27 - $21.23 $29,783 - $61,567	2,900 Added 181.25%	4,500 $66,000
Q3 2019 Oct 28, 2019	BUY	$9.83 - $14.82 $983 - $1,482	100 Added 6.67%	1,600 $15,000
Q2 2019 Aug 09, 2019	BUY	$12.9 - $20.8 $17,169 - $27,684	1,331 Added 787.57%	1,500 $20,000
Q1 2019 May 10, 2019	SELL	$17.7 - $24.93 $131,528 - $185,254	-7,431 Reduced 97.78%	169 $3,000
Q4 2018 Feb 05, 2019	BUY	$19.05 - $36.45 $140,970 - $269,730	7,400 Added 3700.0%	7,600 $171,000
Q3 2018 Nov 07, 2018	SELL	$34.41 - $44.23 $66,273 - $85,186	-1,926 Reduced 90.59%	200 $7,000
Q2 2018 Aug 10, 2018	SELL	$39.21 - $50.29 $88,340 - $113,303	-2,253 Reduced 51.45%	2,126 $83,000
Q3 2017 Oct 17, 2017	BUY	$23.08 - $34.92 $101,067 - $152,914	4,379	4,379 $152,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.